Biosimilar Competition Does Not Reduce Patient Out-of-Pocket Costs for Biologic Drugs
DrugPatentWatch – Pharmaceutical and Biotechnology Business Intelligence - Ein Podcast von DrugPatentWatch
Kategorien:
A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research, conducted by Dr. Kimberly Feng and colleagues, aimed to investigate whether the introduction of biosimilars led to lower OOP spending for patients using biologics. The […] Source
